CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Viral Specific T-cells (VSTs)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03883906
NCT03883906Phase 2Completed

Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant

Children's Hospital Medical Center, Cincinnati·interventional·Posted Mar 21, 2019·Updated Dec 13, 2022

In Brief

A Phase 2 clinical trial evaluating Viral Specific T-cells (VSTs) for Allogeneic Stem Cell Transplant and Viral Infection. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to prevent viral infections that may happen after allogeneic stem cell transplant. Allogeneic means the stem cells come from another person. VSTs are cells specially designed to fight viral infections that may happen after a stem cell transplant (SCT). Stem cell transplant reduces your ability to fight infections. Viral infections are a common problem after transplant and can cause significant complications. Moreover, treatment of viral infections is expensive and time consuming, with families often administering prolonged treatments with intravenous anti-viral medications, or patients requiring prolonged admissions to the hospital. The medicines can also have side effects like damage to the kidneys or reduction in the blood counts, so in this study we are trying to find a way to prevent these infections.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 21, 2019
Enrollment StartMar 16, 2019
Primary CompletionOct 31, 2020
Study CompletionOct 1, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.3 years ago

Interventions

Viral Specific T-cells (VSTs)biological

VSTs will be infused into stem cell transplant recipients